HIV Prevention Trials Network (HPTN) has reported positive results from the HPTN 074 trial, which evaluated an integrated intervention of psychosocial counselling and supported referrals for anti-retroviral therapy at any CD4 cell count and substance use treatment for people living with HIV who inject drugs against locally available standard of care.
The randomised, open-label controlled trial enrolled people who inject drugs in Ukraine, Indonesia and Vietnam.
A total of 502 people living with HIV and 806 people who received drug injections entered the trial over 15 months and were monitored for 12 to 24 months following inclusion.
As part of the trial, patients were distributed in two arms, intervention and standard of care.
Primary goals of the trial comprised estimating incidence in the standard of care arm and evaluating the uptake of an integrated HIV prevention intervention.
Results of the trial showed that at 52 weeks from enrolment, subjects in the intervention arm almost doubled their anti-retroviral therapy usage, viral suppression and medication-assisted treatment usage compared to the standard of care arm.
Mortality was also reported to be reduced among intervention arm subjects and their partners compared to the standard of care arm subjects and partners.
No new HIV infections were found among the partners of intervention arm subjects, though seven partners in the standard of care arm were found to be infected with HIV.
HPTN co-principal investigator Myron Cohen said: “The HPTN 074 study assessed the feasibility of an integrated intervention for people living with HIV who inject drugs to reduce HIV transmission to their HIV-uninfected injection partners.
“These study findings related to anti-retroviral therapy use and HIV prevention are promising, and this and other interventions are needed to get people living with HIV who inject drugs into care for their own health and to stop transmission of the virus.”
The US National Institutes of Health (NIH) units US National Institute of Allergy and Infectious Diseases (NIAID) and US National Institute on Drug Abuse (NIDA) have provided fund for the HPTN 074 trial.